Pierre Fabre Group, Affimed deal

Affimed’s AbCheck s.r.o. subsidiary and Pierre Fabre expanded their 2014 deal granting Pierre Fabre rights to develop and commercialize antibodies discovered by AbCheck using AbSeive technology against undisclosed targets from Pierre Fabre (see BioCentury, April 7, 2014).

Under the expanded agreement, AbCheck will use its AbSieve and AbAccel discovery and optimization platforms to deliver two or more antibodies a year against undisclosed targets provided by Pierre Fabre. The three-year discovery period can be extended to up to five years. ...